River Cities Capital Funds, a growth equity firm investing in high-potential healthcare and IT companies, is pleased to announce the final closing of its fifth fund. Fund V has reached a $200 million hard cap.
Dan Fleming, Managing Director of River Cities, says,
“With a $200M fund, River Cities is a significant player pursuing investments in small, relatively underserved growth equity rounds. The larger fund allows us to continue to expand the investment team as well as our opportunity set.”
River Cities’ founders Glen Mayfield and Ted Robinson will remain active in Fund V. With over 100 investments made in companies like Inspiris and Advanced Biomarker (see full investment portfolio here), the firm’s investment formula has led to premium returns while maintaining a low loss ratio. Some of the firm’s other investments include OrthoHelix, Simbionix, Suros Surgical, EndoChoice and Orthoscan.
In launching this largest fund to date, River Cities is expanding its professional team and adding three new companies to its Fund V portfolio. Tissue Tech is the only new healthcare company so far.
